Medical Condition News RSS Feed - Medical Condition News

Public volunteers to highlight their role in improving care for patients at Sheffield Consumers in Research event

Public volunteers to highlight their role in improving care for patients at Sheffield Consumers in Research event

RESEARCH-active members of the public are to showcase how their vital work helps shape clinical research projects and improves care for patients at a free drop-in event in Sheffield City Centre on Wednesday 22 April. [More]
Roseroot extract may be beneficial for treating major depressive disorder

Roseroot extract may be beneficial for treating major depressive disorder

Rhodiola rosea (R. rosea), or roseroot, may be a beneficial treatment option for major depressive disorder (MDD), according to results of a study in the journal Phytomedicine led by Jun J. Mao, MD, MSCE, associate professor of Family Medicine, Community Health and Epidemiology and colleagues at the Perelman School of Medicine of University of Pennsylvania. [More]
Veterans with PTSD at higher risk of developing heart failure

Veterans with PTSD at higher risk of developing heart failure

In a study of more than 8,000 veterans living in Hawaii and the Pacific Islands, those with posttraumatic stress disorder had a nearly 50 percent greater risk of developing heart failure over about a seven-year follow-up period, compared with their non-PTSD peers. [More]
Experts unveil strategic roadmap to advance treatments for people with lymphoma

Experts unveil strategic roadmap to advance treatments for people with lymphoma

A committee of lymphoma experts today unveiled a strategic roadmap identifying key priority areas in both infrastructure and research that will be critical for advancing treatments for people with lymphoma. [More]
Anti-diabetic medication activates brain sensors, promotes weight gain

Anti-diabetic medication activates brain sensors, promotes weight gain

Medication used to treat patients with type II diabetes activates sensors on brain cells that increase hunger, causing people taking this drug to gain more body fat, according to researchers at Georgia State University, Oregon Health and Science University, Georgia Regents University and Charlie Norwood Veterans Administration Medical Center. [More]
Study identifies common causes of hospital readmissions following joint replacements procedures

Study identifies common causes of hospital readmissions following joint replacements procedures

A new study from researchers at NYU Langone's Hospital for Joint Diseases identifies common causes of hospital readmissions following total hip and knee arthoplasty procedures. [More]
Arthritis & Osteoporosis NSW to hold Clinical Update for 2015 for health professionals

Arthritis & Osteoporosis NSW to hold Clinical Update for 2015 for health professionals

Arthritis is a condition that affects over 1.1 million people in NSW and over 3 million people across Australia and with an ageing population, that figure is projected to reach 7 million by 2050. Arthritis is a condition which affects people across all ages, backgrounds, men and women alike. [More]
New tool can measure cardiovascular risk in persons aged 40 or older

New tool can measure cardiovascular risk in persons aged 40 or older

For the first time, scientists have developed a new risk score that can predict the 10-year risk of developing heart disease or having a stroke in persons aged 40 years or older in any world country. [More]
Zyga reports commercial use of modernized SImmetry Sacroiliac Joint Fusion System for low back pain

Zyga reports commercial use of modernized SImmetry Sacroiliac Joint Fusion System for low back pain

Zyga Technology, Inc., a medical device company focused on the design, development and commercialization of minimally invasive devices to treat underserved conditions of the lumbar spine, today announced the launch and first commercial use of an updated SImmetry Sacroiliac Joint Fusion System. The surgery was performed by Dr. Brett Menmuir. [More]
apceth begins Agenmestencel-T Phase II clinical trial in gastrointestinal cancer patients

apceth begins Agenmestencel-T Phase II clinical trial in gastrointestinal cancer patients

apceth, a global leader in engineered cell therapies, today announced the successful completion of the Phase I and initiation of the Phase II part of its ongoing monocentric Phase I/II clinical trial TREAT-ME 1 with the engineered cell therapeutic product Agenmestencel-T, at the Klinikum Grosshadern in Munich. [More]
NHS England launches online directory to support people with mental health conditions

NHS England launches online directory to support people with mental health conditions

Yesterday, the new NHS Choices Mental Health Apps Library was launched to the public. Big White Wall was among the first five mental health services to be featured in this online directory. [More]
Research reveals why people with type 1 diabetes are unable to control blood glucose levels

Research reveals why people with type 1 diabetes are unable to control blood glucose levels

TEACHING people with type 1 diabetes how to embed lifelong habits such as carbohydrate counting into everyday life rather than as part of week-long education programmes could significantly reduce their risk of complications from the disease, according to new research. [More]
Regeneron announces FDA approval of EYLEA (aflibercept) Injection for diabetic retinopathy

Regeneron announces FDA approval of EYLEA (aflibercept) Injection for diabetic retinopathy

Regeneron Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has approved EYLEA (aflibercept) Injection for the treatment of diabetic retinopathy in patients with diabetic macular edema (DME). In 2014, the FDA granted EYLEA Breakthrough Therapy designation and Priority Review for the treatment of diabetic retinopathy in patients with DME. [More]
GFT505 demonstrates dose-dependent efficacy on primary endpoint in phase 2 NASH trial

GFT505 demonstrates dose-dependent efficacy on primary endpoint in phase 2 NASH trial

GENFIT, today announces topline results of the phase 2 GOLDEN-505 trial in NASH. Due to the unexpected rate of resolution of NASH in patients randomized to placebo who had early NASH (NAS of 3, placebo response rate>57%), along with the high number of sites for a limited sample size, the study as initially designed did not enable the trial to meet directly the primary endpoint. [More]
Updated guidelines for diagnosis, treatment of medullary thyroid carcinoma released

Updated guidelines for diagnosis, treatment of medullary thyroid carcinoma released

A Task Force convened by the American Thyroid Association released updated guidelines for the diagnosis and treatment of medullary thyroid carcinoma (MTC). The current document is the first revision of the original guidelines published in 2009. [More]
Philip Low to be recognized with AACR Award for Outstanding Achievement in Chemistry in Cancer Research

Philip Low to be recognized with AACR Award for Outstanding Achievement in Chemistry in Cancer Research

The American Association for Cancer Research will recognize Philip S. Low, PhD, with the ninth annual AACR Award for Outstanding Achievement in Chemistry in Cancer Research at the AACR Annual Meeting 2015, to be held in Philadelphia, April 18-22. [More]
Helsinn, Mundipharma sign distribution and license agreement for anamorelin

Helsinn, Mundipharma sign distribution and license agreement for anamorelin

Helsinn, a Swiss Group focused on building quality cancer care, and Mundipharma, today announce that they have entered into a distribution and license agreement for the exclusive rights to anamorelin in China, Hong Kong and Macao. [More]
Novo Nordisk announces U.S. launch of Novoeight for people living with hemophilia A

Novo Nordisk announces U.S. launch of Novoeight for people living with hemophilia A

Novo Nordisk today announced the company will launch Novoeight (Antihemophilic Factor [Recombinant]) in the United States for people living with hemophilia A. [More]
LEO Pharma A/S announces regulatory submission of  ENSTILAR® for psoriasis in Europe

LEO Pharma A/S announces regulatory submission of ENSTILAR® for psoriasis in Europe

ENSTILAR® has the potential to be the first cutaneous foam approved for the treatment of psoriasis vulgaris. [More]
Study shows high-fat diet may increase risk for depression, psychiatric disorders

Study shows high-fat diet may increase risk for depression, psychiatric disorders

Can the consumption of fatty foods change your behavior and your brain? High-fat diets have long been known to increase the risk for medical problems, including heart disease and stroke, but there is growing concern that diets high in fat might also increase the risk for depression and other psychiatric disorders. [More]
Advertisement
Advertisement